Breaking News Instant updates and real-time market news.

MRK

Merck

$62.51

-0.04 (-0.06%)

10:15
04/21/17
04/21
10:15
04/21/17
10:15

Observations at VA shows Merck's Zepatier has high SVR for HCV

Merck announced the presentation of findings from a retrospective database analysis of patients with chronic hepatitis C virus, HCV, infection who were administered ZEPATIER in the U.S. Department of Veterans Affairs, VA, healthcare system. For the evaluable population, 95.6% of veterans treated with ZEPATIER achieved the primary outcome of sustained virologic response, SVR, defined as undetectable HCV RNA at least twelve weeks after the end of treatment. For patients with no HCV RNA measurements at or after 12 weeks, the analysis used HCV RNA measurements available at least four and less than 12 weeks after the end of treatment. The response rates in the real-world setting of the VA supplement the overall findings from the controlled clinical studies of ZEPATIER. These findings will be presented today in an oral session at The International Liver Congress 2017 being held in Amsterdam, the Netherlands. Analysis of data from real-world medical settings can provide useful insights to supplement knowledge gained from randomized clinical trials," said Susan Shiff, senior vice president, center for observational and real-world evidence, Merck. "These data from a real-world VA setting add to the body of evidence on ZEPATIER and help deepen scientific understanding of the treatment of this complex disease affecting diverse, sometimes difficult to treat, patient populations."

  • 22

    Apr

  • 02

    May

  • 03

    May

  • 07

    May

  • 10

    May

  • 27

    May

  • 09

    Jun

  • 14

    Jun

MRK Merck
$62.51

-0.04 (-0.06%)

04/03/17
JPMS
04/03/17
NO CHANGE
JPMS
Overweight
Incyte trial news 'another clear positive,' says JPMorgan
JPMorgan analyst Cory Kasimov views the announcement of epacadostat and nivolumab combo moving into Phase 3 studies in first-line non-small cell lung cancer as well as first-line head and neck cancer in 2017 as "another clear positive" for Incyte (INCY). The stock in early trading is up 5% to $140.73. The news expands the breadth of the epacadostat combinations beyond just Merck (MRK) and could ease fears that Bristol-Myers (BMY) is only focused on its internal molecule, Kasimov tells investors in a research note. The analyst continues to be encouraged by Incyte's progress in immuno-oncology and keeps an Overweight rating on the shares.
04/04/17
RBCM
04/04/17
NO CHANGE
RBCM
Incyte price target raised to $157 from $138 at RBC Capital
RBC Capital analyst Simos Simeonidis raised his price target on Incyte (INCY) after Incyte and Bristol-Myers (BMY) announced that they would conduct Phase III trials of the combination of Incyte's epacadostat and Bristol-Myers' Opdivo in 1L lung and head-and-neck cancer. The analyst notes that Merck last week made a similar announcement regarding the use of epacadostat and Merck's Keutruda in additional Phase III trials. Simeonidis keeps an Outperform rating on Incyte.
04/04/17
STFL
04/04/17
NO CHANGE
STFL
NewLink Genetics should be bought on weakness after data, says Stifel
Stifel analyst Stephen Willey said NewLink Genetics' (NLNK) combination of indoximod and Merck's (MRK) pembrolizumab in patients with treatment-naive melanoma demonstrated an overall response rate, or ORR, that is "essentially identical" to the previously-reported results from the Incyte (INCY)-Merck study of epacadostat/pembrolizumab. The lower rate of complete responses he doesn't "find terribly surprising" given what is already known about the current indoximod formulation, he tells investors. Willey, who views today's weakness as an interesting buying opportunity ahead of P1/2 data on the atezolizumab + GDC-0919 combination, keeps a Buy rating on Newlink shares.
04/20/17
JEFF
04/20/17
NO CHANGE
Target $51
JEFF
Underperform
Jefferies lowers Merck estimates, drops target to $51
Jefferies analyst Jeffrey Holford lowered his earnings estimates for Merck by up to 3% citing concerns on pricing for Januvia/Janumet. The analyst notes that his mid-term estimates are now up to 11% below consensus. Holford expects Keytruda, Januvia and Gardasil to miss expectations Q1. He cut his price target for Merck to $51 from $52 and keeps an Underperform rating on the name.

TODAY'S FREE FLY STORIES

AMD

AMD

$13.12

0.04 (0.31%)

, TSLA

Tesla

$375.10

-9.9 (-2.57%)

15:57
09/20/17
09/20
15:57
09/20/17
15:57
Periodicals
Tesla working with AMD on self-driving car AI chip, CNBC says »

Tesla (TSLA) is using AMD…

AMD

AMD

$13.12

0.04 (0.31%)

TSLA

Tesla

$375.10

-9.9 (-2.57%)

NVDA

Nvidia

$187.35

-0.2 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

AMD

AMD

$13.12

0.04 (0.31%)

, TSLA

Tesla

$375.10

-9.9 (-2.57%)

15:54
09/20/17
09/20
15:54
09/20/17
15:54
Periodicals
Breaking Periodicals news story on AMD, Tesla »

Tesla working with AMD on…

AMD

AMD

$13.12

0.04 (0.31%)

TSLA

Tesla

$375.10

-9.9 (-2.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

15:50
09/20/17
09/20
15:50
09/20/17
15:50
General news
More from Yellen: »

More from Yellen: FOMC…

VIX

Volatility Index S&P 500 Options

15:40
09/20/17
09/20
15:40
09/20/17
15:40
Options
Active trading in VIX calls as players replace expiring positions »

Active trading in VIX…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:35
09/20/17
09/20
15:35
09/20/17
15:35
General news
Yellen on the FRB »

Yellen on the FRB: she is…

DMPI

DelMar Pharmaceuticals

$1.12

0.0294 (2.70%)

15:33
09/20/17
09/20
15:33
09/20/17
15:33
Syndicate
DelMar Pharmaceuticals announces $10M registered direct offering at-the-market »

DelMar Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$47.94

0.27 (0.57%)

15:30
09/20/17
09/20
15:30
09/20/17
15:30
Options
Far downside put buying in Morgan Stanley »

Far downside put buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 02

    Oct

  • 22

    Oct

JWN

Nordstrom

$46.13

-0.09 (-0.19%)

15:25
09/20/17
09/20
15:25
09/20/17
15:25
Conference/Events
Nordstrom management to meet with Wolfe Research »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BG

Bunge

$71.38

-1.1 (-1.52%)

15:25
09/20/17
09/20
15:25
09/20/17
15:25
Options
Bunge call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:25
09/20/17
09/20
15:25
09/20/17
15:25
General news
More from Yellen on inflation »

More from Yellen on…

WFC

Wells Fargo

$53.95

0.591 (1.11%)

15:22
09/20/17
09/20
15:22
09/20/17
15:22
Hot Stocks
Chair Yellen calls Wells Fargo actions 'unacceptable' »

Fed Chair Janet Yellen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 12

    Oct

  • 22

    Oct

  • 29

    Nov

  • 15

    Jan

15:20
09/20/17
09/20
15:20
09/20/17
15:20
General news
The FOMC dot-plot projections »

The FOMC dot-plot…

$NSD

NASDAQ Market Internals

15:17
09/20/17
09/20
15:17
09/20/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$75.04

-0.96 (-1.26%)

15:16
09/20/17
09/20
15:16
09/20/17
15:16
Recommendations
Alnylam analyst commentary  »

Alnylam price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

$NYE

NYSE Market Internals

15:16
09/20/17
09/20
15:16
09/20/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LII

Lennox

$170.00

4.17 (2.51%)

15:14
09/20/17
09/20
15:14
09/20/17
15:14
Conference/Events
Lennox management to meet with Wolfe Research »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

VXX

iPath S&P 500 VIX Short-Term Futures

$41.28

0.37 (0.90%)

15:10
09/20/17
09/20
15:10
09/20/17
15:10
Options
Notable put write in longer-term options on the Short-term VIX ETN »

Notable put write in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:09
09/20/17
09/20
15:09
09/20/17
15:09
General news
Yellen repeats intention to serve out term as chair »

Fed Chair Yellen added…

DLPH

Delphi

$100.88

-0.02 (-0.02%)

, BBRY

BlackBerry

$9.14

-0.12 (-1.30%)

15:05
09/20/17
09/20
15:05
09/20/17
15:05
Hot Stocks
Delphi confirms autonomous driving partnership agreement with BlackBerry »

Delphi Automotive (DLPH)…

DLPH

Delphi

$100.88

-0.02 (-0.02%)

BBRY

BlackBerry

$9.14

-0.12 (-1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

UAA

Under Armour

$16.43

-0.38 (-2.26%)

15:00
09/20/17
09/20
15:00
09/20/17
15:00
Options
Under Armour attracts a bullish option play as the slide in shares continues »

Under Armour attracts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

14:55
09/20/17
09/20
14:55
09/20/17
14:55
General news
Fed Chair Yellen reiterated the FOMC statement »

Fed Chair Yellen…

MLHR

Herman Miller

$34.95

0.1 (0.29%)

14:49
09/20/17
09/20
14:49
09/20/17
14:49
Options
Herman Miller options imply 9.6% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

SPX

S&P 500

14:47
09/20/17
09/20
14:47
09/20/17
14:47
General news
Yellen says Fed has commitment to raising inflation to 2% »

Federal Reserve Chair…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHD

Church & Dwight

$49.66

-0.91 (-1.80%)

14:47
09/20/17
09/20
14:47
09/20/17
14:47
Syndicate
Breaking Syndicate news story on Church & Dwight »

Church & Dwight files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 07

    Nov

CSBR

Champions Oncology

$3.38

-0.21 (-5.85%)

14:45
09/20/17
09/20
14:45
09/20/17
14:45
Hot Stocks
Champions Oncology receives $2M contract from HHS contract 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.